Drug Trial Radar · NCT04102501
A Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Friedreich's Ataxia
Last checked: Nov 19, 2026Latest source record: May 27, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
65
Actual
Start
Oct 30, 2019
Primary completion
Aug 23, 2021
Study completion Aug 23, 2021
Sponsor
- Lead sponsor
- Biojiva LLCIndustry
- Sponsor type
- Industry
- First posted
- Sep 25, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the Efficacy, Long Term Safety and Tolerability of RT001 in subjects with Friedreich's Ataxia
Conditions
- Friedreich's Ataxia
Interventions
RT001Drug
RT001 is encapsulated 9-cis, 12-cis-11,11-D2-linoleic acid ethyl ester, which is a site specific (C11) di-deutero synthetic homologue of LA ethyl ester. Each capsule contains 960 mg of RT001.
PlaceboDrug
The placebo product is composed of encapsulated USP safflower oil. The placebo capsules are identical in appearance and size to RT001.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to 11 Months in Maximum Consumption of Oxygen (mlO2/kg/Min) Using Cardiopulmonary Exercise Testing (CPET)Time frame: 11 months
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Collaborative Neuroscience Network, LLC
Long Beach, California
UCLA
Los Angeles, California
University of Florida
Gainesville, Florida
USF Ataxia Research Center
Tampa, Florida
University of Iowa Stead Family Children's Hospital
Iowa City, Iowa
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.